- PROFESSOR Psychiatry
- Dr. Frangou serves as Professor of Psychiatry and Chief of the Psychosis Research Program in the Division of Psychiatric Genomics in the Department of Psychiatry.
A leading authority on neuroimaging in schizophrenia and bipolar disorder, Dr. Frangou was recruited to Mount Sinai to establish a Clinical and Translational Psychosis Program. By building on Mount Sinai’s strengths in clinical investigation, the program aims to transfer research in genetics, neuroimaging, and neurobiology into clinical trials and clinical care.
Dr. Frangou has published highly innovative research on the use of neuroimaging as a diagnostic and evaluation tool for psychosis. Her work has marked out the neural pathways associated with disease expression, vulnerability, and resilience and their association with known genetic risk factors. This body of work represents important paradigm shifts in refining conceptual models for psychosis and has the potential to reduce public skepticism of psychiatry and the stigmatization of patients.
Prior to joining Mount Sinai, Dr. Frangou was Professor of Psychiatry and Head of the Section of Neurobiology of Psychosis at King’s College London. During her tenure, Dr. Frangou led two research programs at the Institute of Psychiatry in London—Vulnerability Indicators for Psychosis and Vulnerability Indicators for Bipolar Disorders—that examined biological markers associated with the diagnosis and genetic risk within and between mood disorders and psychosis. She also served as Consultant Psychiatrist at South London and Maudsley NHS Foundation Trust where she oversaw an 18-bed inpatient unit for patients with recurrent mood and psychotic disorders.
Dr. Frangou had a significant mentoring role in her previous post as Training Program Director for trainees on a dual doctorate and clinical certification tract, which established the national and international reputation of the Institute of Psychiatry in training. In her new position, Dr. Frangou will help train the next generation of translational neuroscientists and clinicians in psychosis.
Affective and Non-affective Psychosis
Multimodal data analyses
Biological predictors of diagnosis and treatment response
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Frangou during 2014 and/or 2015. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Scientific Advisory Board:
- Enzymotec, Ltd.; Janssen-Cilag (Johnson & Johnson)
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.
Icahn Medical Institute Floor 4 Room 36
1425 Madison Avenue
New York, NY 10029